The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Low‐dose naltrexone for the treatment of fibromyalgia: Findings of a small, randomized, double‐blind, placebo‐controlled, counterbalanced, crossover trial assessing daily pain levels
Abstract
Objective: To determine whether low dosages (4.5 mg/day) of naltrexone reduce fibromyalgia severity as compared with the nonspecific effects of placebo. In this replication and extension study of a previous clinical trial, we tested the impact of low‐dose naltrexone on daily self‐reported pain. Secondary outcomes included general satisfaction with life, positive mood, sleep quality, and fatigue. Methods: Thirty‐one women with fibromyalgia participated in the randomized, double‐blind, placebo‐controlled, counterbalanced, crossover study. During the active drug phase, participants received 4.5 mg of oral naltrexone daily. An intensive longitudinal design was used to measure daily levels of pain. Results: When contrasting the condition end points, we observed a significantly greater reduction of baseline pain in those taking low‐dose naltrexone than in those taking placebo (28.8% reduction versus 18.0% reduction; P = 0.016). Low‐dose naltrexone was also associated with improved general satisfaction with life (P = 0.045) and with improved mood (P = 0.039), but not improved fatigue or sleep. Thirty‐two percent of participants met the criteria for response (defined as a significant reduction in pain plus a significant reduction in either fatigue or sleep problems) during low‐dose naltrexone therapy, as contrasted with an 11% response rate during placebo therapy (P = 0.05). Low‐dose naltrexone was rated equally tolerable as placebo, and no serious side effects were reported. Conclusion: The preliminary evidence continues to show that low‐dose naltrexone has a specific and clinically beneficial impact on fibromyalgia pain. The medication is widely available, inexpensive, safe, and well‐tolerated. Parallel‐group randomized controlled trials are needed to fully determine the efficacy of the medication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients
Beck, A. T., Steer, R. A., Ball, R., & Ranieri, W. F. (1996) · Journal of Personality Assessment · doi:10.1207/s15327752jpa6703_13 · Cited by 5,965
Central sensitization: implications for the diagnosis and treatment of pain
Woolf, C. J. (2011) · Pain · doi:10.1016/j.pain.2010.09.030 · Cited by 4,771
Wolfe, F., Clauw, D. J., Fitzcharles, M., Goldenberg, D. L., Katz, R. S., Mease, P., Russell, A. S., Russell, I. J., Winfield, J. B., & Yunus, M. B. (2010) · Arthritis Care & Research · doi:10.1002/acr.20140 · Cited by 3,952
Kettenmann, H., Hanisch, U.-K., Noda, M., & Verkhratsky, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00011.2010 · Cited by 3,547
Ponomarev, E. D., Veremeyko, T., Barteneva, N., Krichevsky, A. M., & Weiner, H. L. (2011) · Nature Medicine · doi:10.1038/nm.2266 · Cited by 787
Fibromyalgia and overlapping disorders: The unifying concept of central sensitivity syndromes
Yunus, M. B. (2007) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2006.12.009 · Cited by 780
Levesque, S., Taetzsch, T., Lull, M. E., Kodavanti, U., Stadler, K., Wagner, A., Johnson, J. A., Duke, L., Kodavanti, P., Surace, M. J., et al. (2011) · Environmental Health Perspectives · doi:10.1289/ehp.1002986 · Cited by 371
Liu, B., Du, L., & Hong, J.-S. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39275-4 · Cited by 347
Comparative Efficacy and Harms of Duloxetine, Milnacipran, and Pregabalin in Fibromyalgia Syndrome
Häuser, W., Petzke, F., & Sommer, C. (2010) · The Journal of Pain · doi:10.1016/j.jpain.2010.01.002 · Cited by 216
Politis, M., Pavese, N., Tai, Y. F., Kiferle, L., Mason, S. L., Brooks, D. J., Tabrizi, S. J., Barker, R. A., & Piccini, P. (2011) · Human Brain Mapping · doi:10.1002/hbm.21008 · Cited by 212
Cited by
Fibromyalgia: A Clinical Review
Clauw, D. J. (2014) · JAMA · doi:10.1001/jama.2014.3266 · Cited by 1,674
Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment
Sarzi-Puttini, P., Giorgi, V., Marotto, D., & Atzeni, F. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-00506-w · Cited by 793
Evidence for brain glial activation in chronic pain patients
Loggia, M. L., Chonde, D. B., Akeju, O., Arabasz, G., Catana, C., Edwards, R. R., Hill, E., Hsu, S., Izquierdo-Garcia, D., Ji, R.-R., et al. (2015) · Brain · doi:10.1093/brain/awu377 · Cited by 503
Complex regional pain syndrome
Bruehl, S. (2015) · BMJ · doi:10.1136/bmj.h2730 · Cited by 362
Bair, M. J., & Krebs, E. E. (2020) · Annals of Internal Medicine · doi:10.7326/aitc202003030 · Cited by 298
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain
Younger, J., Parkitny, L., & McLain, D. (2014) · Clinical Rheumatology · doi:10.1007/s10067-014-2517-2 · Cited by 277
Self-citationFibromyalgia and related conditions
Clauw, D. J. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.03.014 · Cited by 259
Review of pharmacological therapies in fibromyalgia syndrome
Häuser, W., Walitt, B., Fitzcharles, M.-A., & Sommer, C. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4441 · Cited by 188
Current and Emerging Pharmacotherapy for Fibromyalgia
Tzadok, R., & Ablin, J. N. (2020) · Pain Research and Management · doi:10.1155/2020/6541798 · Cited by 122
“Inhibition of microglial activation by naltrexone or naloxone therefore has an anti-inflammatory effect through the decrease in production of neurotoxic chemicals [66, 67], which is suggested to contribute to its analgesic effect [25].”
BackgroundDeshpande, S., Rivera, D. E., Younger, J. W., & Nandola, N. N. (2014) · Translational Behavioral Medicine · doi:10.1007/s13142-014-0282-z · Cited by 24
Self-citation
Metadata
- Authors
- Younger, J., Noor, N., McCue, R., & Mackey, S.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2013-01-28
- Volume
- 65
- Issue
- 2
- Pages
- 529-538
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1994291650
- Cited by
- 207
- References
- 13
- FWCI
- 9.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.